Region: Africa & Middle East

It’s not all bad news for biopharma IP monetisation during coronavirus slowdown

Oncology licensing, smaller acquisitions and abundant venture capital provide means of commercialising innovation during M&A decline

13 August 2020

The advantages and disadvantages of WIPO PROOF

The World Intellectual Property Organization rolled out its new timestamping solution in May and while it has a lot going for it, there are downsides too

19 June 2020

Takeda offloads yet more “non-core” assets with other deals likely to follow

The Japanese big pharma continues to divest drug rights to pay down its debt and fund desperately needed innovation

18 June 2020

How IAM will bring together global IP leaders this September

Join us for IPBC Connect – best-in-class value creation strategies, coming to you from the people who know, throughout the month

17 June 2020

We name the world's top patent lawyers, attorneys, practices and firms

The 2020 edition of the IAM Patent 1000 features in-depth analysis of the markets in 48 key jurisdictions and is based on thousands of submissions, interviews and client references

11 June 2020

IAM benchmarking survey 2020

Featured in Community Insight

Our annual snapshot of the industry keeps the EPO at the top of the big five but suggests that the shine may have come off Andrei Iancu’s reign

08 June 2020

1,000 US patent club 2020

Featured in Portfolio Data

IAM and ktMINE reunite to rank every company with at least 1,000 US grants

08 June 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments

21 May 2020

The hedge fund-backed patent taking aim at Quibi looks solid, but not spectacular

Lawsuit against the billion dollar video streaming start-up is set to keep the headline writers busy and, according to IAM analysis, could have been in the works for a long time

13 May 2020

Johnson & Johnson, Gilead and Roche are the world’s antiviral patent leaders

A covid-19 vaccine could be produced by anyone, but only a few major players had been actively strengthening and building their portfolios before the pandemic struck

17 April 2020

Unlock unlimited access to all IAM content